Objective To evaluate the efficacy and safety of etonogestrel implant for contraception in patients with uterine myoma.Methods A total of 90 women of childbearing age with uterine fibroids,who had contraceptive needs and visited Shanghai Jiading District Maternal and Child Health Hospital from January 2021 to March 2022 were enrolled.For contraception,30 patients received etonogestrel implant(group A),30 patients used condom(group B)and 30 patients received oral spirosterone ethinylestradiol tablets(group C).The volume of uterine myoma,the level of serum estrogen and progesterone,the drop-out rate of contraceptive measures,the rate of effective contraception,the incidence of adverse reactions and patient satisfaction were compared among three groups at 3 months,6 months and 12 months after taking contraceptive measures.Results There were no significant differences in uterine myoma volume,contraceptive effectiveness rate and prolapse rate among three groups(P＞0.05).There was significant difference in estrogen levels after 6 months and 12 months among three groups(P＜0.05),but not at 3 months after using contraceptive measures(P＞0.05).There were significant differences in progesterone levels among three groups at 3,6 and 12 months after using contraceptive measures(P＜0.05).The main adverse reaction for group A and C was the change of menstrual pattern.The incidence of body mass change,leucorrhea,acne,breast pain,decreased libido and allergy was not significantly different among three groups(P＞0.05).Conclusion For contraception in patients with uterine myoma,etonogestrel implant shows high effective rate,few adverse effects and complications,less fluctuation of estrogen and progesterone levels,high patient satisfaction,and not increasing myoma volume,which is worthy of promotion and application clinically.
维普
万方数据